Evidence map›Paper›PMID 41857590›Full record

ArticleVirology journal2026

In Silico and in vitro antiviral activity of FDA approved drugs from ZINC database against RNA-dependent RNA polymerase of dengue virus.

Alia Uzma, Adiba, Ammara Kausar, Muhammad Waseem Aslam, Liaqat Ali, Mahwish Ali, Asma Saleem Qazi, Abdul Haq, Deeba Amraiz, Emad Rashad Sindi and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alia UzmaDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
AdibaDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Ammara KausarDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Muhammad Waseem AslamDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Liaqat AliDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Mahwish AliDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Asma Saleem QaziDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Abdul HaqMaREI Centre, Sustainability Institute, University College Cork, Cork, T23 XE10, Ireland.
Deeba AmraizDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan. deeba.amraiz@numspak.edu.pk.
Emad Rashad SindiDivision of Clinical Biochemistry, Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, 23890, Saudi Arabia.
Taha AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, 62529, Saudi Arabia.
Magdi E A ZakiDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Kingdom of Saudi Arabia.
Molalign AssefaCentral Ethiopia Agricultural Research Institute, Worabe Agricultural Research Center, P.O. Box. 21, Worabe, Ethiopia. molalensafa@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue is a frequent mosquito borne infection with no antiviral medications approved and drug repurposing is an economical and time-saving method of creating an efficient therapy. This research has chosen RNA-dependent RNA polymerase (RdRp) of non-structural protein 5 (NS5) of dengue virus serotype 2 (DENV-2) as a therapeutic. PyRx software was used to perform virtual screening of FDA-approved drugs available in the ZINC database based on their structure. Out of the top15, doxorubicin and rifamycin were selected as candidate drugs to undergo molecular docking and molecular dynamics (MD) studies. Docking showed binding energies of - 8.9 kcal/mol for doxorubicin and - 8.6 kcal/mol for rifamycin. Simulations of MD confirmed that interactions of doxorubicin with the palm domain of RdRp occur in a stable way, which may result in the inability to promote viral replication. In Vero cells, cytotoxicity tests showed that concentrations below 12.25 µg/mL of doxorubicin were not toxic, whereas higher concentrations had morphological effects with a CC

Indexed as

Antiviral AgentsDengue VirusRNA-Dependent RNA PolymeraseViral Nonstructural ProteinsAnimalsCell SurvivalChlorocebus aethiopsDoxorubicinDrug RepositioningMolecular Docking SimulationMolecular Dynamics SimulationUnited StatesVero CellsVirus ReplicationAntiviral AgentsDoxorubicinNS5 protein, dengue virusRNA-Dependent RNA PolymeraseViral Nonstructural ProteinsCytotoxicityDengue virusDoxorubicinIn silicoRNA-dependent RNA polymeraseVero cells

Identifiers

PMID41857590
PMCPMC13001213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.